Rami Elghandour Biography and Net Worth

Chairman and Chief Executive Officer of Arcellx

Rami joined Arcellx in 2021 and serves as our Chairman and Chief Executive Officer. Most recently, Rami served as President and CEO of Nevro, beginning in 2012. Under his leadership, Nevro grew from a small private company to a public company approaching $400m in revenue and a leader in neuromodulation. Prior to Nevro, Rami was an investor with Johnson & Johnson Development Corporation (JJDC), where he led several investments including Nevro’s Series B Financing and served on the Board of Directors of several private companies including Nevro’s. Prior to joining JJDC, Rami was a Design Engineer for Advanced Neuromodulation Systems, Inc. where he led firmware design and development on several implantable spinal cord stimulators. Rami earned recognition as an EY Entrepreneur of the Year, as one of the top CEOs in the US and as one of the top CEOs for women and diversity. He is a recipient of the Bill Campbell award by Watermark for his influence, impact, and advocacy in promoting women and women’s issues. Rami received an MBA from the Wharton School of Business at the University of Pennsylvania and holds a BS in Electrical and Computer Engineering from Rutgers University School of Engineering.

What is Rami Elghandour's net worth?: The estimated net worth of Rami Elghandour is at least $5.23 million as of April 1st, 2024. Mr. Elghandour owns 69,253 shares of Arcellx stock worth more than $5,231,372 as of December 21st. This net worth estimate does not reflect any other assets that Mr. Elghandour may own. Additionally, Mr. Elghandour receives a salary of $941,670.00 as Chairman and Chief Executive Officer at Arcellx. Learn More about Rami Elghandour's net worth.
How old is Rami Elghandour?: Mr. Elghandour is currently 45 years old. There are 5 older executives and no younger executives at Arcellx. Learn More on Rami Elghandour's age.
What is Rami Elghandour's salary?: As the Chairman and Chief Executive Officer of Arcellx, Inc., Mr. Elghandour earns $941,670.00 per year. Learn More on Rami Elghandour's salary.
How do I contact Rami Elghandour?: The corporate mailing address for Mr. Elghandour and other Arcellx executives is , , . Arcellx can also be reached via phone at 240-327-0603 and via email at [email protected]. Learn More on Rami Elghandour's contact information.
Has Rami Elghandour been buying or selling shares of Arcellx?: Rami Elghandour has not been actively trading shares of Arcellx over the course of the past ninety days. Most recently, Rami Elghandour sold 23,086 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $67.09, for a transaction totalling $1,548,839.74. Following the completion of the sale, the insider now directly owns 69,253 shares of the company's stock, valued at $4,646,183.77. Learn More on Rami Elghandour's trading history.
Who are Arcellx's active insiders?: Arcellx's insider roster includes Jill Carroll (Director), Rami Elghandour (Chairman and Chief Executive Officer), Michelle Gilson (CFO), Christopher Heery (Chief Medical Officer), Kavita Patel (Director), Olivia Ware (Director), and Olivia Ware (Director). Learn More on Arcellx's active insiders.
Are insiders buying or selling shares of Arcellx?: In the last year, insiders at the sold shares 30 times. They sold a total of 853,721 shares worth more than $59,734,002.56. The most recent insider tranaction occured on December, 3rd when Director Kavita Patel sold 1,500 shares worth more than $137,820.00. Insiders at Arcellx own 6.2% of the company. Learn More about insider trades at Arcellx.
Information on this page was last updated on 12/3/2024.

Rami Elghandour Insider Trading History at Arcellx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/1/2024	Sell	23,086	$67.09	$1,548,839.74	69,253
5/31/2023	Sell	2,600	$44.27	$115,102.00	36,169

Rami Elghandour Buying and Selling Activity at Arcellx

Arcellx Company Overview

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $75.54

$73.40

$76.41

50 Day Range

MA: $88.59

$75.21

$106.53

2 Week Range

Now: $75.54

$47.88

$107.37

Volume

1,372,259 shs

Average Volume

491,145 shs

Market Capitalization

$4.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Rami Elghandour Biography and Net Worth

What is Rami Elghandour's net worth?

How old is Rami Elghandour?

What is Rami Elghandour's salary?

How do I contact Rami Elghandour?

Has Rami Elghandour been buying or selling shares of Arcellx?

Who are Arcellx's active insiders?

Are insiders buying or selling shares of Arcellx?